Publications by authors named "Ian S Alexander"
Article Synopsis
- Myeloid-derived suppressor cells (MDSCs) can hinder the effectiveness of immunotherapy, especially in liver tumors, by suppressing the immune response.
- This study shows that targeting liver metastasis through regional infusion of TLR9 agonists, specifically ODN2395, can reduce MDSCs and enhance immune cell activity, improving the immune response.
- Combining TLR9 agonist infusion with systemic anti-PD-1 therapy showed promise for better control of liver metastasis, indicating a potential strategy for improving treatment outcomes in cancer patients.
With the advent of cancer immunotherapy, there has been a major improvement in patient's quality of life and survival. The growth of cancer immunotherapy has dramatically changed our understanding of the basics of cancer biology and has altered the standards of care (surgery, radiotherapy, and chemotherapy) for patients. Cancer immunotherapy has generated significant excitement with the success of chimeric antigen receptor (CAR) T cell therapy in particular.
View Article and Find Full Text PDF